MedTrace Logo

Ethyl-EPA Treatment of Prodromal Patients

NCT00634361 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2014-05-22

No results posted yet for this study

Summary

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Conditions

  • Schizophrenia Prodrome

Interventions

DRUG

ethyl-eicosapentaenoic acid

2 mg per day

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Scott W Woods, MD · Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2005-08-31
Completion
2005-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00634361 on ClinicalTrials.gov